Langdon S P, Chubb D, Gescher A, Hickman J A, Stevens M F
Toxicology. 1985 Feb;34(2):173-83. doi: 10.1016/0300-483x(85)90166-0.
Aspects of the toxicology of N-methylformamide (NMF), an investigational antitumour agent, were studied in mice. After injection of NMF at its LD10 (800 mg/kg) dosage the total peripheral white blood cell and platelet counts were unchanged in BALB/c mice. A mild granulocytosis was seen in this strain after administration of the LD50 (2300 mg/kg) dosage. Plasma activity of the enzyme sorbitol dehydrogenase in BDF1 mice was markedly increased after either a single injection of not less than 800 mg/kg or a chronic treatment of not less than 400 mg/kg/day over 5 days indicating the drug to be hepatotoxic. Plasma activities of L-alanine and L-aspartate aminotransferases were also increased after the chronic treatment. Chronic administration of NMF was less hepatotoxic than single dose administration of the same total dose and also increased the antitumour efficacy of NMF against the M5076 sarcoma. These results indicate that the maximum therapeutic benefit of NMF might be obtained by the use of chronic schedules and that the drug is not myelosuppressive.
对一种处于研究阶段的抗肿瘤药物N - 甲基甲酰胺(NMF)的毒理学方面进行了小鼠实验研究。以其LD10(800毫克/千克)剂量注射NMF后,BALB/c小鼠的外周血白细胞总数和血小板计数未发生变化。给予LD50(2300毫克/千克)剂量后,该品系小鼠出现轻度粒细胞增多。在BDF1小鼠中,单次注射不少于800毫克/千克或连续5天每天给予不少于400毫克/千克的慢性治疗后,山梨醇脱氢酶的血浆活性显著增加,表明该药物具有肝毒性。慢性治疗后,L - 丙氨酸和L - 天冬氨酸转氨酶的血浆活性也有所增加。与相同总剂量的单次给药相比,NMF的慢性给药对肝脏的毒性较小,并且还提高了NMF对M5076肉瘤的抗肿瘤疗效。这些结果表明,通过采用慢性给药方案可能获得NMF的最大治疗益处,并且该药物不会引起骨髓抑制。